Percentage of participants who achieved symptomatic remission and maintained symptomatic remission and Kaplan-Meier time course (inset) of attainment (a) and loss (b) of symptomatic remission in the long-term study for all LDX treatment groups. For attainment (a), log rank P-value: .0012; time to first symptomatic remission was calculated from the first day of the study for participants who entered the maintenance phase of the study (n=327), remission status at the start of the long-term study was not determined, and first on-treatment assessment of Attention-Deficit/Hyperactivity Disorder Rating Scale IV was at week 1; P-value indicates overall significant effect among the treatment groups and was not specifically tested between any individual dose groups. For loss (b), log rank P-value: .0385; time to loss of symptomatic remission during the maintenance phase was calculated for participants who met criteria for remission (n=213) at week 4 (visit 5); P-value indicates overall significant effect among the treatment groups and was not specifically tested between any individual dose groups. Abbreviation: LDX=lisdexamfetamine dimesylate.
Mattingly et al. BMC Psychiatry 2013 13:39 doi:10.1186/1471-244X-13-39